Increased operational expenses and reduced cash reserves were cited. Roivant Sciences reports improved EPS for the second ...

Q2 2024 Earnings Call Transcript November 12, 2024 Operator: Good day and thank you for standing by. Welcome to the Roivant ...

Across the recent three months, 5 analysts have shared their insights on Roivant Sciences ROIV, expressing a variety of opinions spanning from bullish to bearish. The following table summarizes their ...

Roivant Sciences Ltd (ROIV) showcases robust financial health with $5.4 billion in cash and no debt, while navigating competitive pressures and strategic opportunities.

Vivek Ramaswamy, a 39-year-old billionaire and key Trump ally, is a vocal supporter of capitalism, advocating for a unified ...

Indian-American entrepreneur and author Vivek Ramaswamy, known for founding Roivant Sciences, has become a prominent figure ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) yesterday. The company’s shares closed yesterday at $11.64. According to TipRanks, Werber is a 5-star ...

Roivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) today. The company’s shares ...

Priovant Therapeutics was formed in 2021 through a partnership between Roivant Sciences and Pfizer (NYSE: PFE) with a focus on developing new treatments for rare autoimmune diseases with high ...

Good day and thank you for standing by. Welcome to the Roivant second-quarter 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I ...